University Of Michigan Rogel Cancer Center

This study tested whether adding venetoclax to standard chemotherapy could help people with newly diagnosed secondary acute myeloid leukemia (AML), a hard-to-treat blood cancer. The goal was to see if at least 60% of patients achieved complete remission. However, the trial was st…

This study tested two drugs, ixazomib and romidepsin, in people with a rare blood cancer called peripheral T-cell lymphoma that had returned or not responded to prior treatments. The trial was stopped early after enrolling only 11 participants, so the best dose could not be deter…

This study tested whether adding the experimental drug CPI-613 to standard chemotherapy (gemcitabine and cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. About 75 participants were planned, but the trial was stopped early. The goa…

This study tested a combination of two drugs (rucaparib and pembrolizumab) as maintenance therapy for people with stage IV non-small cell lung cancer. The goal was to see if this combination could delay cancer progression after initial treatment. The study was terminated early, s…

This study tested fezolinetant, a drug that blocks a brain receptor involved in temperature control, to see if it could reduce hot flashes and night sweats in women with breast cancer taking hormone-lowering medications. The trial planned to enroll many participants but was stopp…